Paul Tudor Jones Taysha Gene Therapies, Inc. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$2.04 - $4.17 $54,333 - $111,063
26,634 New
26,634 $59,000
Q4 2020

Feb 16, 2021
SELL
$19.14 - $28.13 $186,136 - $273,564
-9,725 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$22.4 - $24.47 $217,840 - $237,970
9,725 New
9,725 $218,000

Others Institutions Holding TSHA

# of Institutions
119
Shares Held
136M
Call Options Held
25.9K
Put Options Held
24K
View Full List

About Taysha Gene Therapies, Inc.

TSHA Quotes by TradingView
  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $142M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email